ClinicalTrials.gg
RecruitingNCT07396584Updated Sep 18, 2026

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

A Phase 1/2 interventional study of HMPL-A580 and HMPL-A580 in Solid Tumors, Adult, sponsored by Hutchmed. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Hutchmed · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
186
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.

Read the detailed description

To evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A580 in solid tumors.

To characterize the safety, tolerability, and preliminary efficacy of HMPL-A580 at RDE(s) to determine recommended dose(s) for phase 2 dose (RP2D) or phase 3 dose (RP3D) in participants with selected solid tumors.

02

Conditions studied

  • Solid Tumors, Adult
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understood this study and are able to voluntarily sign the form (ICF);
  2. Male or Female, Age ≥ 18 years;
  3. Histological confirmed, unresectable, advanced or solid tumor
  4. Participants must have at least one per (RECIST) v1.1
  5. ≥ 12 weeks
  6. (ECOG) performance status (PS) of 0-1

Exclusion criteria

Exclusion Criteria:

  1. An established diagnosis of type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
  2. Use strong inhibitors of cytochrome P450 3A4 enzyme (), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug
  3. Major surgery within 28 days prior to the first dose of study drug
  4. Active infection requiring systemic treatment
  5. Participant has received a live within 3 months before study enrollment
  6. History of inflammatory gastrointestinal diseases
  7. Known to any component of HMPL-A580
  8. Pregnant (positive pregnancy test) or lactating;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    Part A(Phase I) Dose Escalation

    Drug: HMPL-A580

  • Experimental
    Part B(Phase IIa) Dose Expansion/Dose Optimization

    Drug: HMPL-A580

Interventions

  • DrugHMPL-A580

    Part A(Phase I) Dose Escalation Enrolled participants will receive HMPL-A580 treatment in a dose escalation setting initially at 6 predefined dose levels.

  • DrugHMPL-A580

    Part B(Phase IIa) Dose Expansion/Dose Optimization Evaluate the safety and preliminary anti-tumor activity of HMPL-A580 in selected solid tumors.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and/or recommended dose(s) for expansion(RDE)

    To evaluate the safety, tolerability, and MTD) and/or RDE of HMPL-A580 in solid tumors

    Time frame: Approximately 12 months

  2. Overview of Treatment-emergent Adverse Events (TEAEs)

    To characterize the safety of HMPL-A580 at RDE(s)

    Time frame: Approximately 12 months

  3. Objective Response Rate (ORR)

    To characterize the tolerability, and preliminary efficacy of HMPL-A580 at RDE(s)

    Time frame: At least 8 weeks post dose of first participant up to approximately 24 months

  4. Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A580

    To characterize the safety, tolerability, and preliminary efficacy of HMPL-A580 at RDE(s) to determine recommended dose(s) for phase 2 dose (RP2D) or phase 3 dose (RP3D) in participants with selected solid tumors.

    Time frame: Approximately 12 months

Secondary outcomes

  1. disease control rate (DCR)

    To assess the preliminary efficacy of HMPL-A580 in solid tumors

    Time frame: Approximately 2 years

  2. progression-free survival (PFS)

    To assess the preliminary antitumor activity of HMPL-A580 in selected solid tumors

    Time frame: Approximately 2 years

07

Study locations

9 of 14 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2026
First posted
Feb 9, 2026
StartActual
Mar 4, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 30, 2029
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07396584
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Mar 4, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Sep 18, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion